Ep. 35 - GLP-1 Medications and Breast Cancer Risk: Breaking Down a Landmark New Study

Ep. 35 - GLP-1 Medications and Breast Cancer Risk: Breaking Down a Landmark New Study

Dr. Tim Sayed walks through a recently accepted study from the Journal of Clinical Oncology Practice showing that GLP-1 medications like Ozempic, Mounjaro, and Zepbound are associated with a significant reduction in breast cancer incidence in overweight women. The paper, led by researchers at the University of Pennsylvania, analyzed electronic health records from roughly 111,000 women ages 45 to 80 with a BMI over 25, comparing breast cancer outcomes between those who had GLP-1 prescriptions and those who did not. The reduction in incidence held across age, race, ethnicity, BMI, breast density, and diabetes status. Dr. Sayed is careful to note what the study is and isn't: it's a retrospective observational cohort, not a randomized controlled trial, and the authors themselves say prospective trials are the necessary next step. He examines the proposed biological mechanisms, how GLP-1 drugs may inhibit cancer cell proliferation and reduce systemic inflammation, and draws a comparison to tamoxifen's established but side-effect-heavy role in breast cancer prevention. He also raises open questions about duration of use, what happens when patients stop, affordability at a population level, and whether pharmaceutical companies have the incentive to pursue formal cancer prevention trials. For patients already navigating GLP-1 treatment or breast health decisions, the findings are worth understanding clearly, even before the full picture is in. Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com [https://info@timsayedmd.com/]Website: timsayedmd.com [https://www.timsayedmd.com/]Instagram: @timsayedmd [https://www.instagram.com/timsayedmd/]YouTube: @Timsayedmd [https://www.youtube.com/channel/UCWmKAMqZIuVzzgkZUAz1cqg/videos]Facebook: Tim Sayed MD [https://www.facebook.com/timsayedmd/]

Ep. 34 - Food Noise, GLP-1 Medications, and the Set Point: Why Weight Comes Back

Dr. Tim Sayed walks through a recent New York Times article on food noise — the persistent mental chatter about eating that many people with obesity describe as relentless — and what GLP-1 medications like semaglutide and tirzepatide appear to do to quiet it. Drawing on both his clinical experience prescribing these medications and his own personal use of them, Sayed unpacks the concept of the set point: the weight a body seems to naturally gravitate toward, which researchers believe may be dysregulated in obesity. The piece raises a question Sayed finds genuinely unresolved — if GLP-1s are suppressing food noise by resetting the set point, what exactly is being reset, and where in the brain is that happening? Patient accounts from the article illustrate how dramatic the shift can feel — and how quickly food noise returns when the medications stop. Sayed doesn't frame this as a failure of the drugs. He's more interested in what it reveals about the underlying biology, and whether behavioral changes adopted during treatment can outlast the medication itself. He also touches on the broader compulsion research emerging around GLP-1s — gambling, alcohol, smoking — and what it might mean that a single drug class appears to quiet such different urges. The honest takeaway here isn't a clean answer but a more precise version of the question: the drugs work, the biology is real, and the mechanisms still aren't fully understood. Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com [https://info@timsayedmd.com/]Website: timsayedmd.com [https://www.timsayedmd.com/]Instagram: @timsayedmd [https://www.instagram.com/timsayedmd/]YouTube: @Timsayedmd [https://www.youtube.com/channel/UCWmKAMqZIuVzzgkZUAz1cqg/videos]Facebook: Tim Sayed MD [https://www.facebook.com/timsayedmd/]

Ep. 33 - GLP-1 Side Effects Patients Are Actually Reporting and What Reddit Data Reveals

Dr. Tim Sayed walks through an April 2026 study published in Nature that analyzed over 410,000 Reddit posts from people using semaglutide and tirzepatide, using AI language models to extract and categorize what patients were actually saying about their experiences on these medications. The study identified roughly 67,000 self-reporting users, and among them, 43.5% described at least one side effect, with nausea leading at 37%, followed by fatigue, vomiting, constipation, and diarrhea. What makes this study notable, and what Sayed spends real time on, is where the real-world data diverges from the clinical trial record. Fatigue appeared far more commonly in Reddit posts than in formal trial reporting. Reproductive symptoms including irregular periods, mid-cycle bleeding, and heavy cycles emerged as a signal in about 4% of users reporting any side effect, something not well captured in current drug labeling. Temperature-related complaints like chills and hot flashes showed up as well, which the study authors connected speculatively to glucagon's known role in thermogenesis. Sayed is careful to carry the study's own caveats: selection bias is real, Reddit skews younger and American, and voluntary self-reporting cannot establish true prevalence. The broader point he lands on is practical. Prescribers should know what patients are reading and talking about, because those conversations are already shaping what people expect and ask about in the clinic. Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com [https://info@timsayedmd.com/]Website: timsayedmd.com [https://www.timsayedmd.com/]Instagram: @timsayedmd [https://www.instagram.com/timsayedmd/]YouTube: @Timsayedmd [https://www.youtube.com/channel/UCWmKAMqZIuVzzgkZUAz1cqg/videos]Facebook: Tim Sayed MD [https://www.facebook.com/timsayedmd/]

Ep. 32 - Breast Implant Illness and Explant Surgery: One Patient's Journey Through Symptoms, Revisions, and Recovery

Dr. Tim Sayed speaks with Rachel Blogg, a licensed psychotherapist and athlete who spent roughly three and a half years navigating breast augmentation, multiple revisions, capsular contracture, implant malposition, and eventually explant surgery before finding relief from symptoms she hadn't initially connected to her implants at all. Rachel's account moves through the full arc — from her original decision to augment after breastfeeding two children, to a series of escalating complications including bottoming out, repeated capsular contracture, and an unsanctioned implant exchange that left her significantly asymmetric and heavier, unable to exercise, and experiencing joint pain severe enough that she underwent four separate trigger finger surgeries that, in retrospect, may never have been necessary. Dr. Sayed contextualizes what Rachel experienced — biofilm theory, the mechanics of under-muscle placement and restricted breathing, and why complete capsulectomy matters in explant surgery — while being careful not to overstate what the evidence currently supports about breast implant illness. Rachel describes symptom resolution that began in the recovery room and continued over the following years: finger pain gone, hair regrowing, thyroid levels stabilizing, and twenty-two pounds lost without changing her approach to diet or training. The conversation turns honestly toward the psychological dimension — radical acceptance as a clinical concept, body image work, the role of a supportive partner, and why Rachel, a DBT therapist herself, waited a full year before pursuing her final surgery. The episode doesn't resolve the broader debate around BII, but it doesn't need to. What it offers is one carefully observed account of what recovery from implants can actually look like. Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com [https://info@timsayedmd.com/]Website: timsayedmd.com [https://www.timsayedmd.com/]Instagram: @timsayedmd [https://www.instagram.com/timsayedmd/]YouTube: @Timsayedmd [https://www.youtube.com/channel/UCWmKAMqZIuVzzgkZUAz1cqg/videos]Facebook: Tim Sayed MD [https://www.facebook.com/timsayedmd/]

Ep. 31 - Breast Implant Removal and the Flat Chest Decision: What Explant Surgery Really Looks Like

Dr. Tim Sayed opens with a published personal account from a 56-year-old runner and author who had saline implants placed in the early 2000s and chose, two decades later, to have them removed and stay flat. The story moves through familiar territory for explant patients — the original decision made from insecurity, the body changes that followed breastfeeding, the capsular contracture that eventually developed, and the years it took to arrive at a choice that felt genuinely her own. Sayed doesn't frame the original augmentation as a mistake, but he is candid about how often external pressure — cultural, familial, sometimes from a partner — shapes these decisions in ways patients don't fully recognize at the time. He reflects on why pre-surgical counseling matters, and why the question of motivation deserves more attention than it typically gets in a cosmetic surgery context. The conversation also touches on a newly launched device, the Explant Express from Applied Medical Technology, a suction retrieval system designed to help surgeons manage ruptured implants during removal more cleanly. Sayed explains the real surgical challenge it's meant to address — silicone containment when the capsule tears — and notes he hasn't used it yet, but sees a plausible role for it in known rupture cases. What runs underneath both segments is the same honest question: what does it actually mean to accept your body as it is, and how long does that usually take. Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com [https://info@timsayedmd.com/]Website: timsayedmd.com [https://www.timsayedmd.com/]Instagram: @timsayedmd [https://www.instagram.com/timsayedmd/]YouTube: @Timsayedmd [https://www.youtube.com/channel/UCWmKAMqZIuVzzgkZUAz1cqg/videos]Facebook: Tim Sayed MD [https://www.facebook.com/timsayedmd/]